PMID- 35547093
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1758-8340 (Print)
IS  - 1758-8359 (Electronic)
IS  - 1758-8340 (Linking)
VI  - 14
DP  - 2022
TI  - Homologous recombination deficiency predicts the response to platinum-based 
      neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a 
      systematic review and meta-analysis.
PG  - 17588359221096253
LID - 10.1177/17588359221096253 [doi]
LID - 17588359221096253
AB  - BACKGROUND: Recent studies have shown that homologous recombination deficiency 
      (HRD) may be correlated with the pathological complete response (pCR) rate. This 
      meta-analysis aimed to determine the predictive value of HRD for the pCR rate in 
      patients with triple-negative breast cancer (TNBC) receiving platinum-based 
      neoadjuvant chemotherapy (NCT). METHODS: Published articles were searched in the 
      PubMed, Embase, Medline, Web of Science, and Cochrane databases up to 1 June 
      2021, and studies reporting the pCR rate for HRD carriers on platinum-based NCT 
      were selected. Odds ratios (ORs) with 95% confidence intervals (CIs) were 
      determined for the pCR rate, clinical response rate, and Grade 3 or higher 
      adverse events (AEs) using the random-effects model. Bias risk was evaluated 
      using the Cochrane Collaboration tool (PROSPERO, registration number 
      CRD42021249874). RESULTS: Seven studies were eligible. The results showed that 
      HRD carriers had higher pCR rates than non-HRD carriers across all treatment arms 
      (OR = 3.84, 95% CI = [1.93, 7.64], p = 0.0001). Among HRD carriers, the pCR rate 
      was higher in patients on platinum-based NCT than in those without platinum 
      exposure (OR = 1.95, 95% CI = [1.17, 3.23], p = 0.01). We did not observe marked 
      pCR improvements in non-HRD carriers. Among HRD carriers, the pCR rates in the 
      mutant and wild-type breast cancer susceptibility gene (BRCA) groups did not 
      differ significantly (OR = 2.00, 95% CI = [0.77, 5.23], p = 0.16), but HRD 
      carriers with wild-type BRCA had a significant advantage over non-HRD carriers on 
      platinum-based NCT (OR = 3.64, 95% CI = [1.83, 7.21], p = 0.0002). CONCLUSION: 
      HRD is an effective predictor of increased pCR rates in platinum-based NCT, 
      especially in wild-type BRCA patients. Adding platinum to NCT for non-HRD 
      carriers can increase the incidence of AEs but may not improve the therapeutic 
      effect.
CI  - (c) The Author(s), 2022.
FAU - Zhang, Liulu
AU  - Zhang L
AD  - Department of Breast Cancer, Cancer Center, Guangdong Provincial People's 
      Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
FAU - Chen, Yuanqi
AU  - Chen Y
AD  - Department of Breast Cancer, Cancer Center, Guangdong Provincial People's 
      Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
FAU - Cheng, Min-Yi
AU  - Cheng MY
AD  - Department of Breast Cancer, Cancer Center, Guangdong Provincial People's 
      Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
FAU - Zhuang, Xiaosheng
AU  - Zhuang X
AD  - Department of Cell and Molecular Biology, School of Life Sciences, The Chinese 
      University of Hong Kong, Shatin, Hong Kong.
FAU - Zou, Jiachen
AU  - Zou J
AD  - Department of Breast Cancer, Cancer Center, Guangdong Provincial People's 
      Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
FAU - Wei, Dannuo
AU  - Wei D
AD  - Department of Social Work & Social Administration, The University of Hong Kong, 
      Pokfulam, Hong Kong.
FAU - Lin, Ying-Yi
AU  - Lin YY
AD  - Department of Breast Cancer, Cancer Center, Guangdong Provincial People's 
      Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
FAU - Zhang, Yi
AU  - Zhang Y
AD  - Department of Breast Cancer, Cancer Center, Guangdong Provincial People's 
      Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
FAU - Wang, Kun
AU  - Wang K
AUID- ORCID: 0000-0001-9851-7080
AD  - Department of Breast Cancer, Cancer Center, Guangdong Provincial People's 
      Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Yuexiu 
      District, Guangzhou 510080, China.
LA  - eng
PT  - Journal Article
DEP - 20220507
PL  - England
TA  - Ther Adv Med Oncol
JT  - Therapeutic advances in medical oncology
JID - 101510808
PMC - PMC9082757
OTO - NOTNLM
OT  - homologous recombination deficiency
OT  - platinum-based chemotherapy
OT  - triple-negative breast cancer
COIS- Conflict of interest statement: The authors declared no potential conflicts of 
      interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2022/05/14 06:00
MHDA- 2022/05/14 06:01
PMCR- 2022/05/07
CRDT- 2022/05/13 11:09
PHST- 2021/11/03 00:00 [received]
PHST- 2022/04/04 00:00 [accepted]
PHST- 2022/05/13 11:09 [entrez]
PHST- 2022/05/14 06:00 [pubmed]
PHST- 2022/05/14 06:01 [medline]
PHST- 2022/05/07 00:00 [pmc-release]
AID - 10.1177_17588359221096253 [pii]
AID - 10.1177/17588359221096253 [doi]
PST - epublish
SO  - Ther Adv Med Oncol. 2022 May 7;14:17588359221096253. doi: 
      10.1177/17588359221096253. eCollection 2022.